Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

• Status: Completed
• Trial end date: 2017-03-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Carla Greembaum, MD; Carla Greenbaum, MD
• Collaborator: Janssen Research & Development, LLC
• Treatments: Antibodies, Monoclonal; Siltuximab

Criteria

Inclusion Criteria:

1. Positive for at least one diabetes-related autoantibody any time since diagnosis, including by not limited to: Glutamate decarboxylase (GAD-65) Insulin, if obtained within 10 days of the onset of exogenous insulin therapy; IA-2; ZnT8

2. Peak stimulated C-peptide level ≥ 0.1 pmol/mL following a mixed meal tolerance test (MMTT) conducted within 60 days of enrollment

3. Females of child-bearing potential must be willing to use effective birth control and refrain from donating eggs for the purposes of assisted reproduction for duration of study.

4. A woman of childbearing potential must have a negative serum (β-human chorionic gonadotropin [β-hCG]) or urine pregnancy test at screening and prior to dosing.

5. During the study, and for 3 months after receiving the study agent, a woman must agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction.

6. Willing and able to give informed consent for participation.

Exclusion Criteria:

1. History of severe reaction or anaphylaxis to human, humanized or murine monoclonal antibodies;

2. History of malignancy or serious uncontrolled cardiovascular disease or hypertension, nervous system, pulmonary, renal, or gastrointestinal disease, or significant dyslipidemia despite therapy;

3. Any history of recent (within 3 months) serious bacterial, viral, fungal, or other opportunistic infections;

4. History or serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C;

5. Positive QuantiFERON or PPD TB test, history of tuberculosis, or active TB infection;

6. Active infection with EBV ;

7. Active infection with CMV;

8. Diagnosis of liver disease or elevated hepatic enzymes, confirmed by repeat tests, as defined by ALT, AST, or both > 1.5 x the upper limit of age-determined normal (ULN) or total bilirubin > ULN;

9. Any of the following hematologic abnormalities, confirmed by repeat tests:

• White blood count <3,000/μL or >14,000/μL

• Lymphocyte count <500/μL

• Platelet count <150,000 /μL

• Hemoglobin <8.5 g/dL or > or = to 17 g/dL

• Neutrophil count <2,000 cells/μL

10. Females who are pregnant or lactating;

11. Receipt of live vaccine (e.g. varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette-Guérin, and small pox) in the 6 weeks before treatment;

12. Receipt of non-live vaccine in the 4 weeks before treatment;

13. Any medical or psychological condition that in the opinion of the Sponsor Investigator would interfere with the safe completion of the trial;

14. Receipt of an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months or 5 half-lives before enrollment or is currently enrolled in the treatment stage of an investigational study;

15. Receipt of any immune-modulating biologic drug within 3 months of enrolling in the study.